In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis

International Journal of Antimicrobial Agents

Volumn 17, Issue 3, 2001, Pages 229-231

  Rodriguez J C ^a   Ruiz, M ^a   Climent, A ^a   Royo, G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Fluoroquinolones; Moxifloxacin; Mycobacterium tuberculosis

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES; SPAIN;

EID: 0035101780     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00337-X     Document Type: Article

References (29)

1. Multidrug-resistant tuberculosis poses challenge
2. Tuberculosis at the end of the 20th century
3. Tuberculosis in the AIDS era
4. Multidrug-resistant tuberculosis
5. Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection
6. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection
7. Newly documented antimicrobial activity of quinolones
8. Activity of quinolones against mycobacteria
9. Fluoroquinolones: a new treatment for tuberculosis
10. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
11. Mycobacterium tuberculosis: evolución de las resistencias en nuestro medio
12. Mycobacterium tuberculosis. Evolución de las resistencias en nuestro medio
13. Current practices in mycobacteriology: results of a survey of state public health laboratories
14. Antimicobacterial agents and susceptibility tests
15. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital
16. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis
17. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
18. Prolonged ciprofloxacin therapy fails to prevent reactivation tuberculosis
19. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations
20. Minimal inhibitory concentration of rifabutin, ciprofloxacin and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan
21. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex
22. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis
23. Ciprofloxacin susceptibility testing by MIC and disk elution of drug-resistant Mycobacterium tuberculosis and Mycobacterium avium complex
24. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin
25. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages
26. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
27. Fluoroquinolones: a new treatment for tuberculosis